Thanks for that Bakerman.

You might find this recent genome-wide association study interesting; http://www.ncbi.nlm.nih.gov/pubmed/25643325 .

The major genetic risk factors for MG were mutations in CTLA4 (CD152) and HLA-DQA1.

CD152 is found on helper T cells and drugs which modulate it have been approved from treatment of other auto-immune diseases. As the authors point out, clinical trials of these drugs in the context of MG look like a good idea.

HLA-DQA1 is a Class II MHC protein. Given the (indirect) role of Class II MHC proteins in antibody production, these mutation might explain why self-reactive antibodies are common in people with MG though I doubt that this will help much in terms of clinical intervention.